Top

Published in:

15-11-2023 | Hodgkin Lymphoma | Original Article

A different perspective on PET/CT before treatment in patients with Hodgkin lymphoma: importance of volumetric and dissemination parameters

Authors: Ayşegül Aksu, Kadir Alper Küçüker, Şerife Solmaz, Bülent Turgut

Published in: Annals of Hematology | Issue 3/2024

Abstract

The aim of this study is to investigate the role of the combination of volumetric and dissemination parameters obtained from pretreatment 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in predicting the interim response and progression status in patients with Hodgkin lymphoma (HL). Pretreatment PET/CT images of HL patients were analyzed with LIFEx software, and volumes of interest (VOIs) were drawn with a fixed SUV 4.0 threshold. MTV, SUVmax, and TLG values were obtained from each VOI. Total MTV (tMTV) was calculated by summing the MTV values in all VOIs, and similarly, total TLG (tTLG) was obtained by summing the TLG values. The distance between the centers of the lesions was noted as Dmax, and the distance between the outermost voxels of the lesions as DmaxVox. tMTV/DmaxVox was calculated by dividing the tMTV value by the DmaxVox value, and tTLG/DmaxVox was calculated by dividing the tTLG value by the DmaxVox value. The correlation of pretreatment PET parameters with response groups (complete/poor) and relapse/progression status (stable/progressive) was statistically evaluated. A total of 52 patients were included in the study. Bulky disease, tMTV, tTLG, and tMTV/DmaxVox values were found to be significantly higher in the poor response group. tMTV > 190.60 ml was found to be the only prognostic factor predicting interim PET response. The tMTV/DmaxVox and tTLG/DmaxVox showed statistically significant differences between the groups with and without progression. tMTV/DmaxVox > 7.70 was found to be the only prognostic factor in predicting relapse/progression. The evaluation of tumor burden and dissemination together in 18F-FDG PET/CT before treatment in patients with HL can help us to predict the results of the patients.

Subocz E, Hałka J, Dziuk M (2017) The role of FDG-PET in Hodgkin lymphoma. Contemp Oncol (Pozn) 21(2):104–114. https://doi.org/10.5114/wo.2017.68618CrossRefPubMed

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM et al (2020) Hodgkin lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18(6):755–781CrossRefPubMed

Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25(24):3746–3752. https://doi.org/10.1200/JCO.2007.11.6525CrossRefPubMed

Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16(9):1514–1523. https://doi.org/10.1093/annonc/mdi272CrossRefPubMed

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32(27):3059–3068. https://doi.org/10.1200/JCO.2013.54.8800CrossRefPubMedPubMedCentral

Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R et al (2018) Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood 131(13):1456–1463. https://doi.org/10.1182/blood-2017-07-795476CrossRefPubMed

Durmo R, Donati B, Rebaud L, Cottereau AS, Ruffini A, Nizzoli ME et al (2022) Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: a radio-genomic study. Hematol Oncol 40(4):645–657. https://doi.org/10.1002/hon.3025CrossRefPubMedPubMedCentral

Zhou Y, Zhu Y, Chen Z, Li J, Sang S, Deng S (2021) Radiomic features of 18F-FDG PET in Hodgkin lymphoma are predictive of outcomes. Contrast Media Mol Imaging 2021:6347404. https://doi.org/10.1155/2021/6347404CrossRefPubMedPubMedCentral

Eertink JJ, van de Brug T, Wiegers SE, Zwezerijnen GJC, Pfaehler EAG, Lugtenburg PJ et al (2022) 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging 49(3):932–942. https://doi.org/10.1007/s00259-021-05480-3CrossRefPubMed

10.

Cottereau AS, Nioche C, Dirand AS, Clerc J, Morschhauser F, Casasnovas O et al (2020) 18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med 61(1):40–45. https://doi.org/10.2967/jnumed.119.229450CrossRefPubMedPubMedCentral

11.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354. https://doi.org/10.1007/s00259-014-2961-xCrossRefPubMed

12.

Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C et al (2018) LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Can Res 78(16):4786–4789CrossRef

13.

Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Littooij AS et al (2014) Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol 25(5):921–927. https://doi.org/10.1093/annonc/mdt533CrossRefPubMed

14.

van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F et al (2022) Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial. BMC Cancer 22(1):672. https://doi.org/10.1186/s12885-022-09758-zCrossRefPubMedPubMedCentral

15.

Tutino F, Puccini G, Linguanti F, Puccini B, Rigacci L, Kovalchuk S et al (2021) Baseline metabolic tumor volume calculation using different SUV thresholding methods in Hodgkin Lymphoma patients: interobserver agreement and reproducibility across software platforms. Nuc Med Com 42(3):284–291. https://doi.org/10.1097/MNM.0000000000001324CrossRef

16.

Triumbari EKA, Morland D, Cuccaro A, Maiolo E, Hohaus S, Annunziata S (2022) Classical Hodgkin lymphoma: a joint clinical and PET model to predict poor responders at ınterim assessment. Diagnostics (Basel) 12(10):2325. https://doi.org/10.3390/diagnostics12102325CrossRefPubMed

17.

Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O et al (2014) Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 41(9):1735–1743. https://doi.org/10.1007/s00259-014-2783-xCrossRefPubMed

18.

Gobbi PG, Ghirardelli ML, Solcia M, Di Giulio G, Merli F, Tavecchia L et al (2001) Image-aided estimate of tumor burden in Hodgkin’s disease: evidence of its primary prognostic importance. J Clin Oncol 19(5):1388–1394. https://doi.org/10.1200/JCO.2001.19.5.1388CrossRefPubMed

19.

Gobbi PG, Broglia C, Di Giulio G, Mantelli M, Anselmo P, Merli F et al (2004) The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer 101(8):1824–1834. https://doi.org/10.1002/cncr.20568CrossRefPubMed

20.

Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L et al (2021) Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†. Ann Oncol 32(3):404–411. https://doi.org/10.1016/j.annonc.2020.11.019CrossRefPubMed

Title: A different perspective on PET/CT before treatment in patients with Hodgkin lymphoma: importance of volumetric and dissemination parameters
Authors: Ayşegül Aksu
Kadir Alper Küçüker
Şerife Solmaz
Bülent Turgut
Publication date: 15-11-2023
Publisher: Springer Berlin Heidelberg
Keyword: Hodgkin Lymphoma
Published in: Annals of Hematology / Issue 3/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-023-05547-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2024

Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management

NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia

Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study

Temporal trends in critical care utilization and outcomes in allogeneic hematopoietic stem cell transplant recipients

Acute liver injury after SARS-CoV-2 vaccination and luspatercept administration in a patient with β-thalassemia

Effect of low skeletal muscle mass on NK cells in patients with acute myeloid leukemia and its correlation with prognosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials